[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse RAPGEF3

Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endomembrane system
Domain PF00027 Cyclic nucleotide-binding domain
PF00610 Domain found in Dishevelled
PF00617 RasGEF domain
PF00618 RasGEF N-terminal motif
Function

Guanine nucleotide exchange factor (GEF) for RAP1A and RAP2A small GTPases that is activated by binding cAMP. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which it activates the PI3K gamma complex and which is involved in angiogenesis. Plays a role in the modulation of the cAMP-induced dynamic control of endothelial barrier function through a pathway that is independent on Rho-mediated signaling. Required for the actin rearrangement at cell-cell junctions, such as stress fibers and junctional actin.

> Gene Ontology
 
Biological Process GO:0000768 syncytium formation by plasma membrane fusion
GO:0001525 angiogenesis
GO:0001885 endothelial cell development
GO:0002064 epithelial cell development
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0003158 endothelium development
GO:0006140 regulation of nucleotide metabolic process
GO:0006195 purine nucleotide catabolic process
GO:0006198 cAMP catabolic process
GO:0006473 protein acetylation
GO:0006611 protein export from nucleus
GO:0006913 nucleocytoplasmic transport
GO:0006949 syncytium formation
GO:0007015 actin filament organization
GO:0007265 Ras protein signal transduction
GO:0009150 purine ribonucleotide metabolic process
GO:0009154 purine ribonucleotide catabolic process
GO:0009166 nucleotide catabolic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009214 cyclic nucleotide catabolic process
GO:0009261 ribonucleotide catabolic process
GO:0009306 protein secretion
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0014074 response to purine-containing compound
GO:0015833 peptide transport
GO:0018105 peptidyl-serine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0019439 aromatic compound catabolic process
GO:0019932 second-messenger-mediated signaling
GO:0019933 cAMP-mediated signaling
GO:0019935 cyclic-nucleotide-mediated signaling
GO:0023061 signal release
GO:0030038 contractile actin filament bundle assembly
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030805 regulation of cyclic nucleotide catabolic process
GO:0030807 positive regulation of cyclic nucleotide catabolic process
GO:0030811 regulation of nucleotide catabolic process
GO:0030813 positive regulation of nucleotide catabolic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030820 regulation of cAMP catabolic process
GO:0030822 positive regulation of cAMP catabolic process
GO:0031032 actomyosin structure organization
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031532 actin cytoskeleton reorganization
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032486 Rap protein signal transduction
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033121 regulation of purine nucleotide catabolic process
GO:0033123 positive regulation of purine nucleotide catabolic process
GO:0033135 regulation of peptidyl-serine phosphorylation
GO:0033138 positive regulation of peptidyl-serine phosphorylation
GO:0033157 regulation of intracellular protein transport
GO:0034242 negative regulation of syncytium formation by plasma membrane fusion
GO:0034655 nucleobase-containing compound catabolic process
GO:0042886 amide transport
GO:0043149 stress fiber assembly
GO:0043543 protein acylation
GO:0044089 positive regulation of cellular component biogenesis
GO:0044270 cellular nitrogen compound catabolic process
GO:0045446 endothelial cell differentiation
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046434 organophosphate catabolic process
GO:0046683 response to organophosphorus
GO:0046700 heterocycle catabolic process
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0046825 regulation of protein export from nucleus
GO:0046827 positive regulation of protein export from nucleus
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0048514 blood vessel morphogenesis
GO:0050708 regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0051017 actin filament bundle assembly
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051222 positive regulation of protein transport
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051496 positive regulation of stress fiber assembly
GO:0051591 response to cAMP
GO:0060142 regulation of syncytium formation by plasma membrane fusion
GO:0060143 positive regulation of syncytium formation by plasma membrane fusion
GO:0061028 establishment of endothelial barrier
GO:0061572 actin filament bundle organization
GO:0071320 cellular response to cAMP
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0072523 purine-containing compound catabolic process
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0090316 positive regulation of intracellular protein transport
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901292 nucleoside phosphate catabolic process
GO:1901342 regulation of vasculature development
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1901983 regulation of protein acetylation
GO:1901985 positive regulation of protein acetylation
GO:1903829 positive regulation of cellular protein localization
GO:1904018 positive regulation of vasculature development
GO:1904951 positive regulation of establishment of protein localization
GO:2000249 regulation of actin cytoskeleton reorganization
Molecular Function GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0017034 Rap guanyl-nucleotide exchange factor activity
GO:0030551 cyclic nucleotide binding
GO:0030552 cAMP binding
Cellular Component GO:0005902 microvillus
GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0030027 lamellipodium
GO:0030175 filopodium
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0031252 cell leading edge
GO:0044448 cell cortex part
GO:0098858 actin-based cell projection
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04015 Rap1 signaling pathway
hsa04024 cAMP signaling pathway
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04670 Leukocyte transendothelial migration
hsa04720 Long-term potentiation
hsa04726 Serotonergic synapse
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-381676: Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-163685: Integration of energy metabolism
R-HSA-354192: Integrin alphaIIb beta3 signaling
R-HSA-1430728: Metabolism
R-HSA-76009: Platelet Aggregation (Plug Formation)
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-392517: Rap1 signalling
R-HSA-422356: Regulation of insulin secretion
R-HSA-162582: Signal Transduction
Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RAPGEF3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RAPGEF3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RAPGEF3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.220.544
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4630.519
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0430.942
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.020.964
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1030.96
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1710.944
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4160.309
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.110.92
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7540.53
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5390.667
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1210.507
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6822.15e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RAPGEF3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RAPGEF3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RAPGEF3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RAPGEF3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RAPGEF3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RAPGEF3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RAPGEF3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRAPGEF3
NameRap guanine nucleotide exchange factor (GEF) 3
Aliases cAMP-GEFI; bcm910; exchange protein directly activated by cAMP 1; RAP guanine-nucleotide-exchange factor (GE ......
Chromosomal Location12q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RAPGEF3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.